Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published-Ahead-of-Print August 26, 2010, DOI:10.2164/jandrol.110.010983

This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
32/1/40    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Napora, J. K.
Right arrow Articles by Basaria, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Napora, J. K.
Right arrow Articles by Basaria, S.

High Dose Isoflavones Do Not Improve Metabolic and Inflammatory Parameters in Androgen Deprived Men with Prostate Cancer

Joshua K. Napora , Ryan G. Short , Denis C. Muller , Olga D. Carlson , Juliana O. Odetunde , Xiaoqiang Xu , Michael Carducci , Thomas G. Travison , Marcello Maggio , Josephine M. Egan , and Shehzad Basaria *

* To whom correspondence should be addressed. E-mail: shehzad.basaria{at}bmc.org.

Background: The profound hypogonadism that occurs with androgen-deprivation therapy (ADT) for prostate cancer (PCa) results in complications such as diabetes and metabolic syndrome that predispose to cardiovascular disease. Since phytoestrogens have been associated with an improvement in metabolic parameters, we evaluated their role in men undergoing ADT. Objective: To evaluate the effects of high-dose isoflavones on metabolic and inflammatory parameters in men undergoing ADT. Methods: This was a randomized, double-blind, placebo-controlled, 12-week pilot study. Participants were randomly assigned to receive 20 g of soy protein containing 160 mg of total isoflavones vs taste-matched placebo (20 g whole milk protein). The study was conducted at a tertiary care center in the United States. Results: Thirty-three men (isoflavones = 17, placebo = 16) undergoing ADT for PCa completed this pilot study. Mean age in the two groups was 69 years and majority of men were Caucasians. Mean duration of ADT in both groups was approximately 2 years (P = 0.70). The two groups were well-matched at baseline. After 12-weeks of intervention, there was no significant difference in either metabolic or inflammatory parameters between the two groups. Conclusion: High-dose isoflavones over a course of 12-weeks do not improve metabolic or inflammatory parameters in androgen deprived men.


Key words: Prostate • Androgen Deprivation • Inflammation • Isoflavones • Metabolic Syndrome • Prostate Cancer






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2010 by The American Society of Andrology.